Jade Biosciences

What Jade Biosciences does

Jade Biosciences is a clinical-stage biotechnology company developing a portfolio of fully human monoclonal antibody therapies targeting validated immunology pathways for autoimmune diseases. The company's pipeline comprises three candidates built on antibody discovery assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. Lead asset JADE101 is an anti-APRIL monoclonal antibody with femtomolar binding affinity and half-life extension technology designed to support every-12-week subcutaneous dosing; it is being evaluated in the JUNIPER Phase 2 trial in IgA nephropathy following positive Phase 1 interim data showing approximately 70% IgA reductions sustained at 12 weeks after a single dose. JADE201 is a half-life extended afucosylated anti-BAFF-R antibody in Phase 1 development for rheumatoid arthritis, and JADE301 is an undisclosed preclinical program with Phase 1 initiation planned for the first half of 2027.

The company is incorporated in Nevada and headquartered in Waltham, Massachusetts, with additional offices in San Francisco and Vancouver, British Columbia. It became a public company on Nasdaq (ticker: JBIO) on April 29, 2025 via a reverse merger with Aerovate Therapeutics and a concurrent approximately $300 million private placement, and has subsequently raised approximately $447 million through additional PIPE and public offerings. Jade serves no commercial customers today — the company is pre-revenue with no approved products — and instead targets patient populations with unmet needs in autoimmune disease, primarily the approximately 169,000 people in the U.S. affected by IgA nephropathy for JADE101 and the broader population of patients with B-cell driven autoimmune diseases for JADE201. Its go-to-market is event-driven, focused on building investor and analyst visibility through healthcare investor conferences, scientific congress presentations, webcasts around clinical milestones, SEC filings, and analyst coverage from firms including UBS, BTIG, Stifel, and H.C. Wainwright. Revenue will eventually be generated through biologic commercialization targeting nephrologists, rheumatologists, and specialty pharmacy channels, but no product revenue is currently recognized and no commercial field force is in place.

Name

Jade Biosciences

Legal name

Jade Biosciences, Inc.

Website

https://jadebiosciences.com

Company type

Public

Founded year

2024

Operating status

Ipo

Headcount range

11–50 employees

Short description

Jade Biosciences is a clinical-stage biotechnology company developing fully human monoclonal antibody therapies for autoimmune diseases, with lead candidate JADE101 in Phase 2 for IgA nephropathy and JADE201 in Phase 1 for rheumatoid arthritis; pre-revenue, publicly traded on Nasdaq as JBIO.

Ownership category

akta.pro rank

Product category

Monoclonal Antibody Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro industry

PRIMARYHLAAAAAA

Monoclonal Antibody Therapeutics (mAbs)

Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

• Monoclonal antibody therapy
• Autoimmune disease treatment
• Clinical-stage biopharmaceuticals
• Immunology drug development
• Antibody-based therapeutics

Headquarters

HQ city

Waltham

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Pre-revenue; clinical-stage: Jade Biosciences is a clinical-stage biotechnology company with no approved products and no product revenue. The company funds operations through equity capital raises (private placements and public stock offerings) and is investing in R&D to advance its pipeline toward potential commercialization. All capital is directed to clinical trials, preclinical studies, manufacturing, research and development, and general corporate purposes.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Core offering

Jade Biosciences is a clinical-stage biotechnology company developing a pipeline of monoclonal antibody therapies targeting autoimmune diseases. The lead candidate, JADE101, is a fully human anti-APRIL antibody for immunoglobulin A nephropathy (IgAN) currently in Phase 2 (JUNIPER), with additional candidates JADE201 (anti-BAFF-R for rheumatoid arthritis) in Phase 1 and JADE301 (undisclosed target) in preclinical development.

Product overview

Jade Biosciences is a clinical-stage biotechnology company focused on developing a pipeline of potentially best-in-class monoclonal antibody therapies aimed at transforming the standard of care for patients living with autoimmune diseases. The company operates as a single-platform portfolio architecture built on antibody assets licensed from Paragon Therapeutics, with three named product candidates: JADE101 (anti-APRIL, lead Phase 2 candidate for IgA nephropathy), JADE201 (anti-BAFF-R, Phase 1 in rheumatoid arthritis), and JADE301 (undisclosed antibody, preclinical). JADE101 serves as the lead candidate driving near-term clinical milestones, with JADE201 and JADE301 extending the pipeline across multiple systemic autoimmune diseases.

Differentiator

Problem solved

Functional benefit

Brands

• JADE101: Lead product candidate; anti-APRIL monoclonal antibody in development for IgA nephropathy.
• JADE201
• JADE301

Products and services

• JADE101 Investigational fully human anti-APRIL monoclonal antibody in development for IgA nephropathy, featuring femtomolar binding affinity and half-life extension for every-12-week subcutaneous dosing; currently in Phase 2 (JUNIPER) with Phase 3 registrational trial planned for first half of 2027.
• JADE201 Investigational half-life extended, afucosylated anti-BAFF-R monoclonal antibody designed to deplete B cells via dual mechanism (BAFF signal blockade plus enhanced ADCC) for autoimmune diseases; first-in-human Phase 1 trial initiated May 2026 in rheumatoid arthritis.
• JADE301 Undisclosed antibody program nominated as Jade's third development candidate, currently in preclinical testing with Phase 1 expected to commence in the first half of 2027.

Quantifiable outcome

• ~70% IgA reductions sustained at 12 weeks after a single subcutaneous dose of JADE101 (700 mg) in healthy volunteers
• +6 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered flagship and minor.

• Paragon Therapeutics (Fairmount)flagshipStrategic or Co-development PartnerJade Biosciences was launched based on antibody discovery-stage assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. The relationship provides Jade with its entire current pipeline including JADE101 (anti-APRIL), JADE201 (anti-BAFF-R), and JADE301 (undisclosed). Fairmount principals (Tomas Kiselak, Chris Cain) sit on Jade's Board of Directors.
• Aerovate TherapeuticsflagshipStrategic or Co-development PartnerOn April 28, 2025, Jade Biosciences completed its reverse merger with Aerovate Therapeutics, a Nasdaq-listed biopharmaceutical company. Aerovate effected a 1-for-35 reverse stock split immediately prior to closing, and pre-merger Aerovate stockholders received a special cash dividend of approximately $2.40 per share (pre-split) or $84.00 per share (post-split). Combined company began trading as Jade Biosciences (Nasdaq: JBIO) at $12.74 on April 29, 2025. Approximately $300 million private placement closed concurrently.
• Paragon Therapeutics (continued)flagshipStrategic or Co-development PartnerJade continues to benefit from assets licensed from Paragon Therapeutics, with Fairmount-affiliated Board members Tomas Kiselak (Founding Partner) and Chris Cain (Director of Research) overseeing the strategic discovery engine relationship.
• PricewaterhouseCoopers LLPminorImplementation/ SI/ Consulting PartnerPricewaterhouseCoopers LLP serves as Jade Biosciences' independent auditor per Investor FAQs.
• ComputershareminorImplementation/ SI/ Consulting PartnerComputershare serves as Jade Biosciences' stock transfer agent per Investor FAQs, managing shareholder records, transfers, address changes, and lost certificate replacements.

Scale indicators14 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Vera Therapeutics: Vera Therapeutics is developing povetacicept, a dual APRIL/BAFF inhibitor currently in Phase 3 for IgA nephropathy — Jade's JADE101 is benchmarked directly against povetacicept on binding affinity (~26-fold higher) and half-life (~8.7x longer). Most directly comparable competitor in the IgAN APRIL pathway space.
• Otsuka Pharmaceutical: Otsuka (via its Visterra acquisition) is developing sibeprenlimab, an anti-APRIL monoclonal antibody in Phase 3 for IgAN. Sibeprenlimab is the second direct APRIL-pathway competitor against JADE101, with which Jade benchmarks its ~379-fold higher binding affinity and ~2.6x longer half-life.
• Apogee Therapeutics: Apogee Therapeutics is a clinical-stage biotech developing monoclonal antibodies (anti-IL-13, anti-OX40L) for atopic dermatitis and inflammatory diseases. Compares as a peer autoimmune antibody platform company with similar development-stage profile and specialty biotech commercialization model.
• Spyre Therapeutics: Spyre Therapeutics is developing engineered antibody therapeutics (anti-TL1A, anti-IL-23) for inflammatory bowel disease. Fairmount partner Tomas Kiselak serves on both Spyre's and Jade's boards, indicating shared discovery engine origins and a directly comparable business model in autoimmune antibody development.
• Oruka Therapeutics: Oruka Therapeutics is developing IL-23 monoclonal antibodies (ORKA-001) for psoriasis and other autoimmune diseases. Lawrence Klein (Oruka CEO) sits on Jade's board; both companies emerged from similar biotech operator networks and pursue best-in-class antibody strategies in immunology.
• Calliditas Therapeutics: Calliditas developed TARPEYO (budesonide delayed-release), the first FDA-approved therapy specifically for IgA nephropathy, positioning them as the established specialty nephrology player. Acquired by Asahi Kasei in 2024. Direct comparator for IgAN market entry strategy and specialty nephrology commercialization.

Emerging players

• Viridian Therapeutics: Viridian Therapeutics develops monoclonal antibodies for autoimmune and rare diseases (anti-IGF-1R for thyroid eye disease, anti-FcRn). Tomas Kiselak chairs Viridian's board and also sits on Jade's board — both companies share Fairmount discovery engine origins. Comparable as an autoimmune-focused antibody platform company.

Broad incumbents

• Chinook Therapeutics: Chinook Therapeutics was a clinical-stage kidney disease biotech acquired by Novartis for $3.5B in 2023. Most of Jade's senior leadership (CEO Frohlich, President R&D King, Board Chair Dobmeier, SVP Regulatory Fauvelle) held senior roles at Chinook, making it the closest operational precedent and strategic blueprint for Jade's development path.
• Novartis: Novartis acquired Chinook Therapeutics for $3.5B in 2023 to gain atrasentan and zigakibart for IgA nephropathy. Now a direct incumbent in the IgAN space with established nephrology commercial infrastructure, representing both a potential exit partner and a competitive threat for Jade.
• AstraZeneca: AstraZeneca is a global biopharmaceutical company with significant autoimmune and immunology franchises, including recent acquisitions (Icosavax, where Jade CLO Balta previously worked; Alexion for rare diseases). Represents a likely strategic acquirer for Jade given biotech acquisition history and large-pharma autoimmune focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/jade-biosciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds5 records

Investors22 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Jade Biosciences